Pfizer and Astellas Announce Landmark Phase 3 Results for PADCEV™ Plus KEYTRUDA™ in Muscle-Invasive Bladder Cancer, Marking Potential Paradigm Shift in Treatment for Cisplatin-Ineligible Patients Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura)…
Stoke Therapeutics and Biogen Dose First Patient in Pivotal Phase 3 EMPEROR Study of Zorevunersen, an Investigational Disease-Modifying Therapy for Dravet Syndrome Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering RNA-based medicines to restore protein expression, and Biogen Inc.…
Melinta Therapeutics to Be Acquired by CorMedix in $300 Million Deal, Marking a Major Milestone in the Acute Care Pharmaceutical Sector Melinta Therapeutics, LLC (“Melinta”), a leading commercial-stage pharmaceutical company known for delivering innovative therapies for acute and life-threatening illnesses,…
Bora Pharmaceuticals Unveils Multi-Year Expansion of Maple Grove Site as U.S. Growth Strategy Advances Post-Upsher-Smith Split Bora Pharmaceuticals Co., Ltd. (TWSE: 6472), a leading global contract development and manufacturing organization (CDMO), has formally launched a multi-year investment plan to significantly…
U.S. Hospitals Achieve Significant Gains in Surgical Patient Outcomes Since 2019, AHA and Vizient Report Shows In a compelling new report released jointly by the American Hospital Association (AHA) and Vizient®, researchers have found that outcomes for hospitalized surgical patients…
Navitus and Costco Pharmacy Partner to Transform Drug Pricing Transparency with Cost-Plus Model Launching in 2026 In a bold move aimed at reshaping the landscape of prescription drug pricing in the United States, Navitus Health Solutions, the nation’s first and…
Arrowhead’s Subsidiary Visirna Transfers Greater China Rights to Plozasiran to Sanofi in Strategic $395 Million Deal Amid Regulatory Milestone in Hypertriglyceridemia In a move poised to reshape the therapeutic landscape for patients with severe lipid disorders in China, Arrowhead Pharmaceuticals,…
BeOne Medicines Achieves Key Regulatory Milestone as EMA Grants PRIME Designation to BTK Degrader BGB-16673 for Waldenstrom’s Macroglobulinemia BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), an emerging global player in oncology therapeutics, has reached a critical milestone in…
Actio Biosciences Receives FDA IND Clearance and Fast Track Designation for ABS-1230 in KCNT1-Related Epilepsy, Marking Major Advancement in Pediatric Precision Medicine Actio Biosciences, a clinical-stage biotechnology company pioneering novel therapies through the lens of genetics and precision medicine, has…
Stallergenes Greer Brings National Spotlight to Peanut Allergy Awareness with Palforzia® Segment on Lifetime TV’s “The Balancing Act” Stallergenes Greer, a global biopharmaceutical company and recognized leader in allergy immunotherapy (AIT), recently announced a major milestone in its public awareness…
DecisionRx and BeneCard PBF Unite to Transform Pharmacy Benefits Through Personalized Medication Optimization In a bold move poised to reshape how pharmacy benefits are delivered and experienced across the U.S., DecisionRx, Inc., a pioneer in Medication Therapy Optimization (MTO), has…
AGC Biologics’ Heidelberg Facility to Manufacture Drug Substance for Phase II Trials of Valneva’s Four-Valent Shigella Vaccine Candidate AGC Biologics, a global contract development and manufacturing organization (CDMO), announced a new partnership with specialty vaccine company Valneva SE (Nasdaq: VALN;…